Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer

PURPOSE: Metastatic breast cancer (MBC) progressing after endocrine therapy frequently activates PI3K/AKT/mTOR pathway. The BOLERO-2 trial showed that everolimus-exemestane achieves increased progression free survival (PFS) compared with exemestane. However, there is great inter-patient variability...

全面介紹

Na minha lista:
書目詳細資料
發表在:PLoS One
Main Authors: Pascual, Tomas, Apellániz-Ruiz, María, Pernaut, Cristina, Cueto-Felgueroso, Cecilia, Villalba, Pablo, Álvarez, Carlos, Manso, Luis, Inglada-Pérez, Lucia, Robledo, Mercedes, Rodríguez-Antona, Cristina, Ciruelos, Eva
格式: Artigo
語言:Inglês
出版: Public Library of Science 2017
主題:
Research Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5519037/
https://ncbi.nlm.nih.gov/pubmed/28727815
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0180192
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍